Organisation paid for research Program year 2021 Source: CMS Open Payments

Vida Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$148,624

56 payments

Through program year 2021, Vida Clinical Trials is reported as receiving $148,624 in research payments, across 56 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$6,021	5
2020	Research	$58,836	29
2019	Research	$83,768	22

Breakdown

Who paid Research payments · program years 2019–2021

Allergan Inc. $148,624 56 payments

Studies the money was for Research payments · program years 2019–2021

A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $70,707 21 payments
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis $30,954 12 payments
A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis $12,008 1 payment
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) $11,942 9 payments
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) $9,454 4 payments
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure $4,817 2 payments
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $3,253 2 payments
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis $1,948 2 payments
12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis $1,734 1 payment
Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis DG $988 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.